1. Search Result
Search Result
Results for "

skin+wound+healing

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17505
    Candesartan Cilexetil
    5 Publications Verification

    TCV-116

    Angiotensin Receptor Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .
    Candesartan Cilexetil
  • HY-N2551

    S-Methylmethionine sulfonium chloride

    Others Inflammation/Immunology
    Vitamin U (S-Methylmethionine sulfonium) chloride is an orally active anti-ulcer agent with antioxidant activity. Vitamin U inhibits adipocyte differentiation. Vitamin U promotes skin wound healing.Vitamin U can be used in the research of gastrointestinal ulceration .
    Vitamin U chloride
  • HY-134508

    mTOR Neurological Disease Cancer
    C24-Ceramide is an orally active competitive binding agonist of PIP4K2C (mTOR complex regulator), thereby activating the mTOR signaling pathway. At the same time, C24-Ceramide changes the membrane morphology by inducing the formation of a partially interlocked gel phase in the phospholipid bilayer. C24-Ceramide can promote the proliferation and migration of keratinocytes to accelerate skin wound healing and drive the proliferation and metastasis of gallbladder cancer cells. The level of C24-Ceramide in serum can be used as a diagnostic marker for gallbladder cancer .
    C24-Ceramide
  • HY-P1290
    PKA Inhibitor Fragment (6-22) amide
    5 Publications Verification

    PKI-(6-22)-amide

    PKA Neurological Disease
    PKA Inhibitor Fragment (6-22) amide is a highly potent and specific competitive inhibitor of PKA, with Ki values of 1.7 nM and 1.6 nM against human and bovine PKA catalytic subunits, respectively. The IC50 of PKA Inhibitor Fragment (6-22) amide targeting bovine PKA is 8.6 nM. PKA Inhibitor Fragment (6-22) amide effectively abolishes PKA activity in mouse brain and spinal cord, and exerts in vivo efficacy via intracerebroventricular administration. PKA Inhibitor Fragment (6-22) amide significantly reverses low-dose morphine analgesic tolerance in mice and blocks photoaffinity labeling of cAMP-dependent protein kinase. PKA Inhibitor Fragment (6-22) amide can be applied to research in fields related to the mechanism of morphine analgesic tolerance and skin wound healing .
    PKA Inhibitor Fragment (6-22) amide
  • HY-110050

    Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization .
    GP1a
  • HY-P11112

    β-catenin Wnt Collagen Inflammation/Immunology
    PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing .
    PTD-DBM
  • HY-132187

    TGF-beta/Smad TRP Channel Apoptosis PAI-1 Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a Kd of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes .
    Sphingosylphosphorylcholine
  • HY-17505R

    TCV-116 (Standard)

    Reference Standards Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology
    Candesartan Cilexetil (Standard) is the analytical standard of Candesartan Cilexetil. This product is intended for research and analytical applications. Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .
    Candesartan Cilexetil (Standard)
  • HY-P11474

    Integrin FAK Akt ERK Metabolic Disease
    FZ1 peptide is an integrin αvβ3 agonist. FZ1 peptide binds to integrin αvβ3, effectively activates FAK, FAK-dependent AKT and ERK1/2 signaling pathways. FZ1 peptide enhances VEGFC-induced endothelial angiogenesis, accelerates diabetic skin wound healing .
    FZ1 peptide
  • HY-W707384

    TCV-116-d11

    Isotope-Labeled Compounds Angiotensin Receptor Apoptosis Cardiovascular Disease Endocrinology
    Candesartan Cilexetil-d11 (TCV-116-d11) is deuterium labeled Candesartan Cilexetil. Candesartan Cilexetil (TCV-116) is an angiotensin II receptor inhibitor. Candesartan Cilexetil ameliorates the pulmonary fibrosis and has antiviral and skin wound healing effect. Candesartan Cilexetil can be used for the research of high blood pressure .
    Candesartan Cilexetil-d11
  • HY-186172

    TRP Channel Calcium Channel Metabolic Disease
    KS0365 is a selective TRPV3 agonist with an EC50 of 5.08 μM. KS0365 does not activate TRPV2 or TRPV4 channels. KS0365 triggers an increase in [Ca 2+]i and accelerates keratinocyte migration. KS0365 can be used in studies related to impaired skin wound healing .
    KS0365

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: